Title: Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian randomization study

Short title: GLP-1R and mental health

Authors:

Guoyi Yang, PhD[a,b*], Stephen Burgess, PhD[c,d], C Mary Schooling, PhD[a,e]

[a] School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

[b] Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

[c] MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

[d] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

[e] Graduate School of Public Health and Health Policy, City University of New York, New York, USA

[*]**Corresponding author: Guoyi Yang, PhD**

Postal address: 1/F, Patrick Manson Building, 7 Sassoon Road, Pokfulam, Hong Kong

Email address: yanggy@connect.hku.hk

Telephone: +852 98147624

ORCID: 0000-0002-4387-386X

Word count: 3514

The number of tables: 0

The number of figures: 4

Abstract

Concerns have been raised about the psychiatric safety of glucagon-like peptide-1 receptor (GLP-1R) agonists, but trial evidence suggests that they ameliorate depressive symptoms. We aimed to assess the associations of GLP-1R activation with mental health well-being and the risk of mental health disorders and substance use disorders. We performed drug-target Mendelian randomization and colocalization analyses using the largest relevant genome-wide association studies and replicated in FinnGen. After correcting for multiple comparisons, genetically predicted lower body mass index (BMI) via GLP-1R activation was associated with a better well-being spectrum (0.06 standard deviation [95% confidence interval 0.03-0.08]), lower risk of depression (odds ratio 0.83 [0.74-0.94]), and lower risk of bipolar disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m^2 decrease in BMI. There was also suggestive evidence that genetically predicted lower BMI via GLP-1R activation was associated with lower risk of substance use disorders. These associations were stronger than the associations for genetically predicted lower BMI and lower glycated hemoglobin (HbA1c) based on genome-wide variants. The posterior probabilities of colocalization of BMI and each outcome at the *GLP1R* gene were 59.3% for the well-being spectrum, 3.8% for depression, and 45.9% for bipolar disorder. However, the posterior probabilities of colocalization were > 80% for the well-being spectrum and bipolar disorder when conditioning on the presence of a variant associated with the outcome. This study provides genetic evidence that GLP-1R activation is associated with better mental health well-being and lower risk of bipolar disorder, possibly beyond its effect on BMI and HbA1c.

(Word count: 246)

Keywords: bipolar disorder, depression, glucagon-like peptide-1 receptor, Mendelian randomization, mental health

Introduction

Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce body weight and blood glucose.[1] Randomized controlled trials (RCTs) have shown cardiovascular and mortality benefits of GLP-1R agonists.[2,3] GLP-1R agonists act on the hindbrain, the hypothalamus, and vagal afferents to suppress food intake and reduce body weight.[4-6] Anti-obesity drugs affecting central nervous systems could have psychiatric effects. For example, the combination of phentermine and topiramate increases depression and anxiety.[7] Rimonabant was withdrawn from the market due to serious psychiatric adverse events.[8] In contrast, the combination of naltrexone and bupropion improves depression[9] and substance use disorder.[10]

Concerns have been raised about the risk of suicidal ideation and self-injury in people using GLP-1R agonists.[11] However, RCTs showed that GLP-1R agonists moderately reduced depressive symptoms in people who are overweight or obese[12] and in people with type 2 diabetes.[13] Animal,[14,15] observational,[16,17] and genetic studies[18] suggested potential benefits of GLP-1R agonists in alcohol use disorder, but RCTs yielded contradictory evidence showing benefits or null effects.[19,20] Early-stage trials are on-going to investigate the efficacy of GLP-1R agonists in individuals with mental illnesses[21] and substance use disorders.[22] A better understanding of the association of GLP-1R activation, the intended target of GLP-1R agonists, with mental health has implications for informing their psychiatric safety and potential repurposing opportunities.

72 To address this gap, we used Mendelian randomization (MR), an instrumental variable
73 analysis with genetic instruments, to obtain less confounded estimates than conventional
74 observational studies.[23] We used MR to assess the associations of GLP-1R activation with
75 mental health outcomes including the well-being spectrum, mental health disorders, and
76 substance use disorders. We further investigated whether any associations were explained by
77 lowering body mass index (BMI) or lowering glycated hemoglobin (HbA1c).
78

79 **Subjects and Methods**

80 ***Ethics approval and consent to participate***

81 All the analyses were conducted using publicly available summary statistics, which does not
82 require ethical approval. Participants of the original studies of publicly available summary
83 statistics provided informed consent.
84

85 ***Study design***

86 MR relies on the instrumental variable assumptions of relevance (the genetic instruments
87 should be related to the exposure), independence (no common cause of the genetic
88 instruments and the outcome exists), and exclusion restriction (the genetic instruments should
89 be independent of the outcome given the exposure).[23] This MR study took advantage of the
90 largest relevant publicly available genome-wide association studies (GWASs) (eTable 1).
91 First, we assessed the associations of GLP-1R activation predicted by *GLP1R* variants with

92 mental health outcomes including the well-being spectrum, mental health disorders, and
93 substance use disorders. We compared these associations with the associations for lower BMI
94 and lower HbA1c predicted by genome-wide variants. Second, we performed colocalization
95 analyses to examine whether any associations found for GLP-1R activation were driven by a
96 shared causal variant affecting both BMI or HbA1c and the outcome at the *GLP1R* gene.[24]
97 Where possible, we conducted sex-specific analyses, because women are more likely to have
98 depression than men,[25] but boys are more likely to develop neurodevelopmental disorders
99 than girls.[26]
100

101 ***Genetic instruments***

102 We selected genetic instruments for GLP-1R activation based on their associations with
103 downstream traits related to drug target effects (BMI and HbA1c), because this approach
104 reduces the risk of the variant-outcome association being lost or confounded by pleiotropic
105 effects.[27] We obtained genetic associations with BMI (N = 806,834) from a meta-analysis of
106 the UK Biobank and GIANT[28] and with HbA1c (N = 344,182) from a GWAS of the UK
107 Biobank.[29] We considered these two sets of instruments separately, because they might
108 represent distinct mechanisms.[30] For primary analyses, we extracted variants in or near (+-
109 1Mb) the *GLP1R* gene that were uncorrelated (r^2<0.001) and genome-wide significantly (p
110 value $<5\times10^{-8}$) associated with BMI to mimic BMI-related mechanisms. We used the same
111 approach based on their associations with HbA1c to select genetic variants mimicking
112 HbA1c-related mechanisms. For sensitivity analyses, we used a less stringent significance

113 threshold for instrument selection (p value < 1×10^{-5}). For comparison, we also extracted
114 genetic instruments for BMI and HbA1c from across the genome (genome-wide variants) that
115 were uncorrelated (r^2 <0.001) and genome-wide significantly (p value <5×10^{-8}) associated
116 with BMI and HbA1c, respectively.
117
118 We used coronary artery disease (CAD) and all-cause mortality as positive control outcomes,
119 because RCTs have shown that GLP-1R agonists reduce cardiovascular events and death.[2,3]
120 We obtained genetic associations with CAD (181,522 cases/984,168 controls) from a meta-
121 analysis of the CARDIoGRAMplusC4D consortium and the UK Biobank.[31] We obtained
122 genetic associations with parental mortality (609,139 cases/403,101 controls), determined by
123 parental attained age and their alive/dead status, from a meta-analysis of the UK Biobank and
124 LifeGen as a measure of all-cause mortality,[32] because it has greater power than participant's
125 mortality.
126
127 ***Genetic associations with mental health outcomes***
128 We obtained sex-combined and sex-specific genetic associations with mental health outcomes
129 from the largest relevant publicly available GWASs (eTable 1).[29,33-47] Primary outcomes
130 included the well-being spectrum, mental health disorders (depression, bipolar disorder, post-
131 traumatic stress disorder (PTSD), schizophrenia, anorexia nervosa, attention deficit
132 hyperactivity disorder (ADHD), autism spectrum disorder, and Tourette's syndrome), and
133 substance use disorders. Secondary outcomes included four dimensions of mental health well-

being (life satisfaction, positive affect, neuroticism, and depressive symptoms) and subtypes of mental health disorders (postpartum depression and bipolar disorder I and II) and substance use disorders (cannabis use disorder and alcohol dependence). Secondary outcomes also included the Alcohol Use Disorders Identification Test (AUDIT) total score, score for alcohol consumption, and score for alcohol problems. We obtained genetic associations with relevant outcomes from the FinnGen R12 for replication,[48] where possible. Genetic associations with binary outcomes obtained using linear regression were transformed into odds ratio (OR) using an established approximation.[49]

MR analysis

We used the F-statistic to assess instrument strength, approximated by the square of SNP-exposure association divided by the square of its standard error.[50] An F-statistic larger than 10 suggests weak instrument bias is unlikely. We aligned SNPs on the same allele for exposure and outcome, and used proxy SNPs (r^2>0.8), where possible, when SNPs were not available in the outcome GWAS. We calculated Wald estimates by dividing genetic association with outcome by genetic association with exposure. We obtained MR estimates by meta-analyzing Wald estimates using inverse variance weighting (IVW) with fixed effects for three SNPs or fewer and random effects for four SNPs or more.[51] To assess the robustness of IVW estimates, we conducted sensitivity analyses using the weighted median,[52] MR Egger,[53] and MR using the robust adjusted profile score (MR-RAPS).[54] We used the Cochran's Q statistic[55] to test heterogeneity in Wald estimates and the MR Egger intercept[53] to assess directional pleiotropy.

155 We used the Steiger filtering to identify the SNPs explaining more variance in the outcome
156 than in the exposure (p value < 0.05).[56] We conducted sensitivity analyses excluding the SNPs
157 identified to assess whether MR estimates were affected by reverse causation. We used a
158 Bonferroni-corrected significance level of α=0.05/10=0.005 given ten primary outcomes. We
159 considered nominally significant associations (p value <0.05) that did not reach Bonferroni-
160 corrected significance as suggestive evidence. We tested differences by sex using a two-sided
161 z-test.[57]
162

163 ***Colocalization***

164 We performed pairwise colocalization analyses in a Bayesian framework to assess whether
165 any associations found for GLP-1R activation were driven by a shared causal variant affecting
166 both BMI or HbA1c and the outcome or were confounded by linkage disequilibrium.[24] We
167 included variants (minor allele frequency >0.1%) in or near (+- 1Mb) the *GLP1R* gene. We set
168 the prior probabilities as recommended, that is 10^{-4} for a variant associated with BMI or
169 HbA1c, 10^{-4} for a variant associated with the outcome, and 10^{-5} for a variant associated with
170 both traits.[24] We assessed the posterior probability of several hypotheses, including H_0 (no
171 association with either trait), H_1, (association with BMI or HbA1c only); H_2, (association with
172 the outcome only); H_3, (associations of two independent variants and one for each trait); H_4
173 (associations of one shared variant with both traits).[24] A posterior probability of H_4 larger than
174 0.80 suggests colocalization.[24] The power to detect colocalization is low when the variants are
175 not strongly associated with the outcome, so we also calculated the posterior probability of

176 colocalization (H_4) conditional on the presence of a variant associated with the outcome as

177 $H_4/(H_2 + H_3 + H_4)$.[58] We reported the posterior probabilities of H_0-H_4 and conditional H_4 and

178 the variant with the largest posterior probability of being the shared causal variant.

179

180 We also used the Hypothesis Prioritisation for multi-trait Colocalization (HyPrColoc)[59] to

181 assess colocalization across multiple traits identified for GLP-1R activation. We set the prior

182 probability for a variant associated with at least one trait as 10^{-4} and the conditional prior

183 probability for a variant associated with an additional trait given that the variant is associated

184 with at least one other trait as 0.02.[59] We reported clusters of putatively colocalized traits and

185 the posterior probability of colocalization.

186

187 All statistical analyses were conducted using R version 4.2.1 and the packages "ieugwasr",

188 "TwoSampleMR", "MendelianRandomization", "mr.raps, "metafor", "coloc", and

189 "hyprcoloc".

190

191 **Results**

192 ***Genetic instruments***

193 For primary analyses, we used two *GLP1R* SNPs (rs17757975 and rs4714290) genome-wide

194 significantly associated with BMI to predict the impact of GLP-1R activation as indicated by

195 lower BMI; we used one *GLP1R* SNP (rs10305518) genome-wide significantly associated

196 with HbA1c to predict the impact of GLP-1R activation as indicated by lower HbA1c (eTable
197 2). For sensitivity analyses, we used three *GLP1R* SNPs for BMI and two *GLP1R* SNPs for
198 HbA1c based on a more lenient significance threshold (p value $< 1\times10^{-5}$) (eTable 2). The
199 *GLP1R* SNPs for BMI were not associated with HbA1c and vice versa (eTable 3), which
200 substantiated that the two sets of genetic instruments represent distinct mechanisms of GLP-
201 1R activation.[30] For comparison, we also extracted 516 (overall), 303 (women), and 256
202 (men) SNPs for BMI and 318 (overall), 200 (women), 174 (men) SNPs for HbA1c from
203 across the genome (eTable 4). The F-statistics of the primary instruments were all >10
204 (eTables 2 and 4).
205
206 In positive control analyses, genetically predicted lower BMI and lower HbA1c via GLP-1R
207 activation were associated with lower CAD risk and all-cause mortality, despite wide
208 confidence intervals (CIs) (eFigure 1). The point estimates for GLP-1R activation were
209 comparable to those for genetically predicted lower BMI and lower HbA1c based on genome-
210 wide variants (eFigure 1 and eTable 5).
211
212 ***Associations of GLP-1R activation with mental health well-being***
213 Genetically predicted lower BMI via GLP-1R activation was associated with a better well-
214 being spectrum, including life satisfaction, positive affect, neuroticism, and depressive
215 symptoms (Figure 1). The association with depressive symptoms was evident specifically in
216 women (eFigure 2). These associations were stronger than the associations for genetically

217 predicted lower BMI using genome-wide variants (Figure 1). However, genetically predicted
218 lower HbA1c via GLP-1R activation had little association with mental health well-being
219 (Figure 1). Sensitivity analyses gave consistent estimates, and the Steiger filtering identified
220 no SNP that explained more variance in the outcome than in the exposure (eTable 6-7).
221

222 ***Associations of GLP-1R activation with the risk of mental health disorders***

223 Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of
224 depression, postpartum depression, bipolar disorder, bipolar disorder I and II, and ADHD
225 (Figure 2). The association with depression was possibly stronger in women than men,
226 although the *p* value for sex difference was 0.35 (eFigure 3). These associations were stronger
227 than the associations for genetically predicted lower BMI using genome-wide variants (Figure
228 2). Genetically predicted lower HbA1c via GLP-1R activation was associated with higher risk
229 of anorexia nervosa but lower risk of Tourette syndrome, with stronger associations than the
230 associations for genetically predicted lower HbA1c using genome-wide variants (Figure 2).
231 These results were robust to different MR methods and the exclusion of SNPs identified by
232 the Steiger filtering (eTable 8).
233

234 ***Associations of GLP-1R activation with the risk of substance use disorders***

235 Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of
236 substance use disorders and lower AUDIT score for alcohol problems (Figure 3). These

237 associations were stronger than the associations for genetically predicted lower BMI using
238 genome-wide variants. However, genetically predicted lower HbA1c via GLP-1R activation
239 had little association with the risk of substance use disorders (Figure 3). Sensitivity analyses
240 using different MR methods and excluding the SNPs identified by the Steiger filtering gave
241 similar interpretations (eTable 9).
242

243 ***Replication***

244 In FinnGen, genetically predicted lower BMI via GLP-1R activation was associated with
245 lower risk of depression, bipolar disorder, PTSD, ADHD, substance abuse, and alcohol
246 dependence (eFigure 4). Genetically predicted lower HbA1c via GLP-1R activation had little
247 association with mental health outcomes except for depression (eFigure 4). Nevertheless, this
248 association with depression was attenuated to null when using the two SNPs extracted based
249 on a more lenient significance threshold (eTable 10).
250

251 ***Colocalization***

252 After correcting for multiple comparisons, genetically predicted lower BMI via GLP-1R
253 activation remained significantly associated with the well-being spectrum, life satisfaction,
254 positive affect, neuroticism, depressive symptoms, depression, bipolar disorder, and bipolar
255 disorder I (p values <0.005). Pairwise colocalization analyses were performed for BMI and
256 each significant outcome in or near the *GLP1R* gene. The posterior probabilities of

257 colocalization were <80% for all the significant outcomes (Figure 4). However, conditioning
258 on the presence of a variant associated with the outcome, the posterior probabilities of
259 colocalization were all >80% except for depression (Figure 4), suggesting that some lack of
260 colocalization was due to limited power. The posterior probabilities of two independent
261 variants associated with each trait were <15% for all the significant outcomes (eTable 11),
262 suggesting that confounding by linkage disequilibrium was unlikely. Across the *GLP1R* gene
263 region, rs4714290, rs847784 (a proxy for rs4714290, $r^2 = 0.89$), or rs17757975 had the largest
264 posterior probability of being the shared causal variant, which substantiated their validity as
265 genetic instruments.
266
267 Multi-trait colocalization analyses were performed across BMI and all the significant
268 outcomes in or near the *GLP1R* gene. We identified BMI, the well-being spectrum, life
269 satisfaction, positive affect, neuroticism, depressive symptoms as a cluster of putatively
270 colocalized traits with the posterior probability of colocalization 51.9%.
271

272 **Discussion**

273 This drug-target MR study suggests that GLP-1R activation is associated with a better well-
274 being spectrum and lower risk of bipolar disorder. We also provide suggestive evidence that
275 GLP-1R activation is associated with lower risk of substance use disorders. These
276 associations are likely beyond the effects of GLP-1R activation on BMI and HbA1c.

We found that genetically predicted GLP-1R activation was associated with a better well-being spectrum, lower risk of depression, and lower risk of bipolar disorder. Consistently, RCTs have shown that GLP-1R agonists moderately reduce depression symptoms in overweight people[12] and in people with type 2 diabetes.[13] A small open-label trial showed that liraglutide, as an adjunct to existing pharmacotherapy, improved cognitive function[60] and brain volumes[61] in people with depression or bipolar disorder. These psychiatric benefits of GLP-1R activation could be driven by the neuroprotective effects of GLP-1 including enhanced neurogenesis, improved barrier function, reduced neuroinflammation, and decreased oxidative stress.[62]

Interestingly, the associations of GLP-1R activation with favorable mental health outcomes were more evident when proxied via BMI than via HbA1c, highlighting the importance of BMI-related mechanisms. A recent study showed that GLP-1R agonists target the hindbrain dorsal vagal complex to decrease food intake and body weight.[4] Actions on the hypothalamus and vagal afferents also contribute to the weight loss on GLP-1R agonists.[5,6] GLP neurons in the dorsal vagal complex moderate stress responses and stimulate hypothalamic-pituitary-adrenal (HPA) axis activity, which has been implicated in the pathology of depression[63] and bipolar disorder.[64] Notably, the HPA axis is also related to cognitive function,[63,64] consistent with an RCT showing that dulaglutide reduces cognitive impairment in people with type 2 diabetes.[65] Additional studies are warranted to elucidate the mechanisms underlying potential

298 benefits of GLP-1R agonists for mental health.

299

300 We found that genetically predicted GLP-1R activation was possibly associated with lower
301 risk of depression specifically in women and lower risk of postpartum depression. We caution
302 that the power to detect sex differences may have been limited by small or unequal sample
303 sizes of sex-stratified GWAS. Women are about twice as likely as men to have depression
304 during their lifetime with the difference starting at puberty.[25] A meta-analysis of RCTs showed
305 that GLP-1R agonists decreased testosterone and increased sex hormone-binding globulin in
306 women with polycystic ovary syndrome,[66] but their effects on estrogen are less clear. Sex
307 hormones might contribute to GLP-1R activation improving depression in women, given their
308 potential roles in modulating serotonergic neurotransmission, cortisol, and oxytocin.[67]

309

310 Genetically predicted GLP-1R activation was suggestively associated with lower risk of
311 ADHD and Tourette syndrome but had a null association with autism spectrum disorder.
312 Although RCTs have shown the short-term (no more than 26 weeks) safety of GLP-1R
313 agonists in children and adolescents,[68] RCTs typically do not capture the long latency of
314 neurodevelopmental disorders. Our study adds to the evidence by showing little adverse effect
315 of lifelong GLP-1R activation on these disorders. However, GLP-1R activation was
316 associated with higher risk of anorexia nervosa when proxied via HbA1c. GLP-1R activation
317 increases insulin secretion and sensitivity and lowers glucose.[69] A previous MR study
318 suggested an inverse association of fasting insulin with the risk of anorexia nervosa,[70]

319 indicating a role of insulin sensitivity.

320

321 We provide suggestive evidence that GLP-1R activation was associated with lower risk of
322 substance use disorders and lower AUDIT score for alcohol problems, which were replicated
323 in FinnGen. Our finding aligns with a recent RCT showed that eight-week treatment with
324 semaglutide reduced alcohol consumption and craving in people with alcohol use disorder.[20]
325 In contrast, another RCT including people with alcohol use disorder showed that 26 weeks of
326 treatment with exenatide did not significantly reduce heavy drinking days, although exenatide
327 attenuated fMRI alcohol cue reactivity in brain areas for drug reward and addiction.[19] Further
328 evidence from RCTs is needed to determine the repurposing opportunities of GLP-1R
329 agonists for treating substance use disorders.

330

331 We presented the MR estimates of GLP-1R activation in effect sizes of BMI or HbA1c
332 reduction for interpretability. However, this scaling does not imply that weight loss or glucose
333 lowering is the sole mechanism of action for the psychiatric effects of GLP-1R activation.
334 Indeed, the associations of GLP-1R activation with mental health outcomes appeared stronger
335 than those expected from lowering BMI and HbA1c. Correspondingly, RCTs have showed
336 that semaglutide reduces cardiovascular events and mortality more than expected from the
337 reduction in body weight,[12] and that GLP-1R agonists outperform other anti-diabetes drugs.[71]
338 Apart from reducing body weight and glucose, GLP-1R agonists also decrease blood pressure,
339 low-density lipoprotein cholesterol, and inflammation and enhance kidney function.[2,3] The

340 multifaceted effects of GLP-1R agonists could be partially explained by 5' adenosine
341 monophosphate-activated protein kinase (AMPK) activation.[72] Taken together, our findings
342 suggest that the psychiatric benefits of GLP-1R activation likely extend beyond its effect on
343 BMI and HbA1c.
344
345 This drug-target MR study comprehensively explored the associations of GLP-1R activation
346 with mental health outcomes. Our investigation has implications for the psychiatric safety and
347 repurposing opportunities of GLP-1R agonists, particularly in people with mental health
348 disorders, who usually have higher risk of obesity and type 2 diabetes but are undertreated.
349 This study has several limitations. First, MR relies on three rigorous assumptions, that is
350 genetic instruments should be related to the exposure, share no common cause with the
351 outcome, and be independent of the outcome given the exposure.[23] The F-statistics were >10,
352 suggesting minimal weak instrument bias. We validated the genetic instruments using CAD
353 and all-cause mortality as positive control outcomes. We used MR methods with different
354 assumptions about instrumental validity, which gave consistent estimates. Second, we selected
355 genetic instruments for GLP-1R activation based on their associations with BMI and HbA1c,
356 but additional underlying factors may explain their psychiatric effects. Instrumenting on BMI
357 and HbA1c could have masked some effects of GLP-1R activation. Third, the small number
358 of genetic instruments for GLP-1R activation, even when applying a more lenient significance
359 threshold for instrument selection, may have limited the detection of possible causal effects.
360 Fourth, we obtained genetic associations with BMI from a meta-analysis of the UK Biobank

361 and GIANT and with HbA1c from the UK Biobank, which overlaps with some outcome
362 GWASs. Two-sample MR methods in a one-sample setting perform well in terms of bias and
363 precision in large biobanks, except for MR Egger which can result in bias reflecting the
364 direction and magnitude of confounding.[73] We replicated the results using outcome GWASs
365 from FinnGen, which has no overlap with the UK Biobank or GIANT. Fifth, the power to
366 detect colocalization was insufficient. However, the posterior probabilities of two independent
367 variants associated with each trait were <15% for all the significant outcomes, suggesting that
368 the associations found were unlikely driven by confounding due to linkage disequilibrium.
369 Sixth, MR can be open to selection bias from selecting on genetic makeup and mental health
370 disorders. Nevertheless, such selection should bias towards a harmful effect of GLP-1R
371 activation, which could not explain its associations with favorable mental health outcomes.
372 Finally, mental health disorders sometimes originate during childhood or adolescence, but
373 GLP-1R agonists are primarily used in adults. Our MR study assessed lifelong effects of
374 GLP-1R activation, which cannot directly inform the short-term effects of GLP-1R agonists.
375 RCTs are warranted to determine the clinical relevance of these findings in the future.
376

377 **Conclusions**

378 This drug-target MR study provides genetic evidence that GLP-1R activation is associated
379 with better mental health well-being and lower risk of bipolar disorder, possibly beyond its
380 effect on BMI and HbA1c.

Acknowledgements

The authors acknowledge Pulit SL, et al., the Neale lab, the CARDIoGRAMplusC4D Consortium, Timmers PR, et al., Baselmans BML, et al., the Psychiatric Genomics Consortium, and FinnGen for their publicly available summary data.

Funding

GY is supported by the American Heart Association Postdoctoral Fellowship (26POST1560184). SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). The funders had no role in the study design, analyses, or interpretation of results.

Competing interests

The authors declared no conflict of interest.

Availability of data and materials

Summary statistics analyzed are available in the website

https://doi.org/10.5281/zenodo.1251813 for BMI, http://www.nealelab.is/uk-biobank/ for HbA1c, https://www.cardiogramplusc4d.org/data-downloads/ for CAD, https://www.ebi.ac.uk/gwas/publications/30642433 for parental mortality, https://www.ebi.ac.uk/gwas/publications/30643256 for mental health well-being, and https://pgc.unc.edu/for-researchers/download-results/ and https://www.finngen.fi/en/access_results for mental health disorders and substance use disorders.

Author contributions

GY and CMS designed the study. GY undertook analyses with feedback from SB and CMS. GY drafted the manuscript with critical feedback and revisions from SB and CMS. All authors read and approved the final version of the manuscript. GY had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Artificial intelligence (AI)-assisted technologies

The authors declared that AI-assisted technologies were not used in this study.

415 **References**

416 1. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and
417 disease. *Nature reviews Endocrinology.* 2018;14(7):390-403.
418 2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular
419 Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24):2221-2232.
420 3. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney
421 outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic
422 review and meta-analysis of randomised trials. *The lancet Diabetes & endocrinology.*
423 2021;9(10):653-662.
424 4. Huang KP, Acosta AA, Ghidewon MY, et al. Dissociable hindbrain GLP1R circuits for
425 satiety and aversion. *Nature.* 2024.
426 5. Burmeister MA, Ayala JE, Smouse H, et al. The Hypothalamic Glucagon-Like Peptide
427 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and
428 Glucose Homeostasis in Mice. *Diabetes.* 2017;66(2):372-384.
429 6. Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of
430 GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia.
431 *Diabetes.* 2016;65(1):34-43.
432 7. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release,
433 phentermine plus topiramate combination on weight and associated comorbidities in
434 overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3
435 trial. *Lancet (London, England).* 2011;377(9774):1341-1352.

436 8. Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular
437 events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet*
438 *(London, England).* 2010;376(9740):517-523.
439 9. Pi-Sunyer X, Apovian CM, McElroy SL, Dunayevich E, Acevedo LM, Greenway FL.
440 Psychiatric adverse events and effects on mood with prolonged-release
441 naltrexone/bupropion combination therapy: a pooled analysis. *International journal of*
442 *obesity (2005).* 2019;43(10):2085-2094.
443 10. Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine
444 Use Disorder. *The New England journal of medicine.* 2021;384(2):140-153.
445 11. European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor
446 agonists. 2023; https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-
447 glp-1-receptor-agonists. Accessed September 20, 2024.
448 12. Wadden TA, Brown GK, Egebjerg C, et al. Psychiatric Safety of Semaglutide for
449 Weight Management in People Without Known Major Psychopathology: Post Hoc
450 Analysis of the STEP 1, 2, 3, and 5 Trials. *JAMA internal medicine.* 2024.
451 13. Chen X, Zhao P, Wang W, Guo L, Pan Q. The Antidepressant Effects of GLP-1
452 Receptor Agonists: A Systematic Review and Meta-Analysis. *The American journal of*
453 *geriatric psychiatry : official journal of the American Association for Geriatric*
454 *Psychiatry.* 2024;32(1):117-127.
455 14. Suchankova P, Yan J, Schwandt ML, et al. The glucagon-like peptide-1 receptor as a
456 potential treatment target in alcohol use disorder: evidence from human genetic

association studies and a mouse model of alcohol dependence. *Translational psychiatry.* 2015;5(6):e583.

15. Aranäs C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. *EBioMedicine.* 2023;93:104642.

16. Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, Rungby J, Jørgensen MB, Osler M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. *Basic & clinical pharmacology & toxicology.* 2022;131(5):372-379.

17. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. *Nature communications.* 2024;15(1):4548.

18. Reitz J, Rosoff DB, Perlstein T, et al. Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study. *Mol Psychiatry.* 2025.

19. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. *JCI insight.* 2022;7(19).

20. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry.* 2025;82(4):395-405.

21. Ganeshalingam AA, Uhrenholt NG, Arnfred S, Gæde PH, Bilenberg N, Frystyk J.

Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo controlled and double-blinded multicentre trial. *BMJ open.* 2024;14(3):e077173.

22. Köhne S, Hillemacher T, Glahn A, Bach P. Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder. *Expert opinion on emerging drugs.* 2024;29(3):219-232.

23. Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. *Statistical methods in medical research.* 2007;16(4):309-330.

24. Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS genetics.* 2014;10(5):e1004383.

25. Kuehner C. Why is depression more common among women than among men? *The lancet Psychiatry.* 2017;4(2):146-158.

26. Bölte S, Neufeld J, Marschik PB, Williams ZJ, Gallagher L, Lai MC. Sex and gender in neurodevelopmental conditions. *Nature reviews Neurology.* 2023;19(3):136-159.

27. Gill D, Dib MJ, Cronjé HT, et al. Common pitfalls in drug target Mendelian randomization and how to avoid them. *BMC medicine.* 2024;22(1):473.

28. Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature.* 2015;518(7538):197-206.

29. UK Biobank (Neale lab). http://www.nealelab.is/uk-biobank/.

30. Patel A, Gill D, Shungin D, et al. Robust use of phenotypic heterogeneity at drug

target genes for mechanistic insights: Application of cis-multivariable Mendelian randomization to GLP1R gene region. *Genetic epidemiology.* 2024;48(4):151-163.

31. Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants. *Nat Genet.* 2022;54(12):1803-1815.

32. Timmers PR, Mounier N, Lall K, et al. Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances. *eLife.* 2019;8.

33. Baselmans BML, Jansen R, Ip HF, et al. Multivariate genome-wide analyses of the well-being spectrum. *Nature genetics.* 2019;51(3):445-451.

34. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. *Nature neuroscience.* 2019;22(3):343-352.

35. Guintivano J, Byrne EM, Kiewa J, et al. Meta-Analyses of Genome-Wide Association Studies for Postpartum Depression. *The American journal of psychiatry.* 2023;180(12):884-895.

36. Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nature genetics.* 2021;53(6):817-829.

37. Nievergelt CM, Maihofer AX, Klengel T, et al. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci.

Nature communications. 2019;10(1):4558.

38. Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature.* 2022;604(7906):502-508.

39. Watson HJ, Yilmaz Z, Thornton LM, et al. Genome-wide association study identifies eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nature genetics.* 2019;51(8):1207-1214.

40. Demontis D, Walters GB, Athanasiadis G, et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. *Nature genetics.* 2023;55(2):198-208.

41. Martin J, Walters RK, Demontis D, et al. A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. *Biological psychiatry.* 2018;83(12):1044-1053.

42. Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for autism spectrum disorder. *Nature genetics.* 2019;51(3):431-444.

43. Yu D, Sul JH, Tsetsos F, et al. Interrogating the Genetic Determinants of Tourette's Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. *The American journal of psychiatry.* 2019;176(3):217-227.

44. Hatoum AS, Colbert SMC, Johnson EC, et al. Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. *Nature Mental health.* 2023;1(3):210-223.

45. Johnson EC, Demontis D, Thorgeirsson TE, et al. A large-scale genome-wide

541 association study meta-analysis of cannabis use disorder. *The lancet Psychiatry.*
542 2020;7(12):1032-1045.
543 46. Walters RK, Polimanti R, Johnson EC, et al. Transancestral GWAS of alcohol
544 dependence reveals common genetic underpinnings with psychiatric disorders. *Nature*
545 *neuroscience.* 2018;21(12):1656-1669.
546 47. Sanchez-Roige S, Palmer AA, Fontanillas P, et al. Genome-Wide Association Study
547 Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two
548 Population-Based Cohorts. *The American journal of psychiatry.* 2019;176(2):107-118.
549 48. Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-
550 phenotyped isolated population. *Nature.* 2023;613(7944):508-518.
551 49. Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of Summary
552 Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio.
553 *Genetics.* 2018;208(4):1397-1408.
554 50. Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR.
555 Assessing the suitability of summary data for two-sample Mendelian randomization
556 analyses using MR-Egger regression: the role of the I2 statistic. *International journal*
557 *of epidemiology.* 2016;45(6):1961-1974.
558 51. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
559 multiple genetic variants using summarized data. *Genetic epidemiology.*
560 2013;37(7):658-665.
561 52. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in

Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genetic epidemiology.* 2016;40(4):304-314.

53. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International journal of epidemiology.* 2015;44(2):512-525.

54. Qingyuan Z, Jingshu W, Gibran H, Jack B, Dylan SS. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. *The Annals of Statistics.* 2020;48(3):1742-1769.

55. Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. *Stat Med.* 2015;34(21):2926-2940.

56. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS genetics.* 2017;13(11):e1007081.

57. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ (Clinical research ed).* 2003;326(7382):219.

58. Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian randomization and colocalization: Review and comparison of approaches. *American journal of human genetics.* 2022;109(5):767-782.

59. Foley CN, Staley JR, Breen PG, et al. A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. *Nature communications.*

583 2021;12(1):764.

584 60. Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvements in objective
585 measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-
586 label study. *Journal of affective disorders.* 2017;207:114-120.

587 61. Mansur RB, Zugman A, Ahmed J, et al. Treatment with a GLP-1R agonist over four
588 weeks promotes weight loss-moderated changes in frontal-striatal brain structures in
589 individuals with mood disorders. *European neuropsychopharmacology : the journal of*
590 *the European College of Neuropsychopharmacology.* 2017;27(11):1153-1162.

591 62. Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions
592 of GIP and GLP1. *Nature reviews Endocrinology.* 2023;19(4):201-216.

593 63. Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical
594 symptomatology and genetic variation predict cognition. *Molecular psychiatry.*
595 2017;22(4):527-536.

596 64. Belvederi Murri M, Prestia D, Mondelli V, et al. The HPA axis in bipolar disorder:
597 Systematic review and meta-analysis. *Psychoneuroendocrinology.* 2016;63:327-342.

598 65. Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on
599 cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.
600 *The Lancet Neurology.* 2020;19(7):582-590.

601 66. Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual
602 cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic
603 review. *BMC endocrine disorders.* 2023;23(1):245.

604 67. Martel MM. Sexual selection and sex differences in the prevalence of childhood
605 externalizing and adolescent internalizing disorders. *Psychological bulletin.*
606 2013;139(6):1221-1259.
607 68. Yugar LBT, Sedenho-Prado LG, da Silva Ferreira IMC, Silva CAM, Sposito AC,
608 Cercato C. The efficacy and safety of GLP-1 receptor agonists in youth with type 2
609 diabetes: a meta-analysis. *Diabetology & metabolic syndrome.* 2024;16(1):92.
610 69. MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The
611 multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.
612 *Diabetes.* 2002;51 Suppl 3:S434-442.
613 70. Adams DM, Reay WR, Geaghan MP, Cairns MJ. Investigation of glycaemic traits in
614 psychiatric disorders using Mendelian randomisation revealed a causal relationship
615 with anorexia nervosa. *Neuropsychopharmacology : official publication of the*
616 *American College of Neuropsychopharmacology.* 2021;46(6):1093-1102.
617 71. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2
618 diabetes: systematic review and network meta-analysis of randomised controlled trials.
619 *BMJ (Clinical research ed).* 2023;381:e074068.
620 72. Schooling CM, Yang G, Soliman GA, Leung GM. A Hypothesis That Glucagon-like
621 Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating
622 Adenosine Monophosphate-Activate Protein Kinase (AMPK). *Life (Basel,*
623 *Switzerland).* 2025;15(2).
624 73. Minelli C, Del Greco MF, van der Plaat DA, Bowden J, Sheehan NA, Thompson J.

The use of two-sample methods for Mendelian randomization analyses on single large datasets. *International journal of epidemiology.* 2021.



Figure 1. IVW MR estimates for the associations of GLP-1R activation with mental health well-being.

BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive associations with the well-being spectrum, life satisfaction, and positive affect and negative associations with neuroticism and depressive symptoms indicate better mental health well-being. Estimates are presented in standard deviation units for mental health well-being per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.



Figure 2. IVW MR estimates for the associations of GLP-1R activation with the risk of mental health disorders.

638 ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

639 hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization; PTSD, post-traumatic stress disorder. Black squares denote

640 genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically

641 predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Estimates are presented as odds ratio per 1-kg/m^2 decrease in BMI

642 or per 1-mmol/mol decrease in HbA1c.

643



Figure 3. IVW MR estimates for the associations of GLP-1R activation with the risk of substance use disorders and AUDIT scores. AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive associations with AUDIT scores indicate higher risk of alcohol use disorders. Estimates are presented in

650 standard deviation unit for substance use disorder risk, as logodds for cannabis use disorder and alcohol dependence, and as log10 transformed

651 score for AUDIT scores per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.



Figure 4. Pairwise colocalization analyses for BMI and each significant outcome at the *GLP1R* gene.

654 BMI, body mass index. Probability for colocalization means the posterior probability of a shared variant associated with both traits; conditional

655 probability means the posterior probability of a shared variant associated with both traits conditional on the presence of a variant associated with

656 the outcome. Given the presence of a shared variant associated with both traits, the labeled variant had the largest probability of being the shared

657 causal variant.